Skip to content
Simpler Grants

No. HT942526ALSRPTDA · Defense Health Agency Contracting Activity - DHACA

Open

DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award

grants.gov listing Full announcement (NOFO)
Dealbreakers No cost share required Audit: not stated Reimbursement-only: not stated
Invitation only
“Invitation to Submit an Application: August 3, 2026” — From the announcement

At a glance

AI summary

This program funds therapeutic development research for amyotrophic lateral sclerosis, from preclinical validation of lead compounds through FDA IND-enabling studies. Applicants must already have lead compounds and proof-of-concept efficacy data in at least one ALS preclinical model, and clinical trials are not allowed. Eligible applicants include U.S. Department of War organizations, foreign and domestic organizations, and for-profit and nonprofit organizations; awards are made to organizations, not individuals. The expected total cost per award is capped at $2.0 million, the maximum period of performance is three years, and cost sharing is not required. Mechanism-specific biomarker development is a required part of the project, but biomarker work for diagnosis, prognosis, or general disease progression alone will not be supported.

AI-generated summary — verify against the announcement

What it funds

  • Science and Technology and other Research and Development
  • Technology & Product Development
  • Patients & People with Health Conditions
  • Researchers & Scholars
  • Biomedical & Disease Research
Official description from grants.gov

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology. Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems. Distinctive Features: Mechanism-specific , predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award . If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported. Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.

Who can apply

  • Unrestricted
Geographic restriction None found in the announcement — likely nationwide